Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 14/20 | 1.00 |
| ▸ | GRM6 | O15303 | 11/20 | 1.00 |
| ▸ | GRM8 | O00222 | 7/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.73 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.73 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eglumetad SCHEMBL15060586 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL16585263 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL13728495 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL481248 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL231157 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL1650783 | 0.98 | GRM2 (0.96) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL30417494 | 0.85 | SLC1A2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL6697973 | 0.80 | GRM2 (0.67) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL4810986 | 0.79 | SLC1A2 (0.66) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL6699648 | 0.79 | GRM2 (0.65) | GRM2GRM3GRM6GRM8SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRM2 1/4885GRM3 3/4885GRM6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.